血清IgG2多组分抗体在系统性红斑狼疮及狼疮肾炎中的前瞻性研究
本研究前瞻性随访36个月,检测新诊断狼疮肾炎(LN)患者91例、SLE患者31例及诊断2年内SLE患者99例的循环IgG2抗体水平。结果显示抗ENO1、抗H2A和抗ANXA1 IgG2与蛋白尿平行下降并在12个月内多恢复正常,而抗dsDNA IgG2持续升高;抗ENO1和抗H2A与高蛋白尿及eGFR降低关联最强,抗dsDNA与肾脏结局参数无关。
要点
- 抗ENO1、抗H2A和抗ANXA1 IgG2随蛋白尿下降并在12个月内多数正常化。
- 抗ENO1和抗H2A与高蛋白尿及eGFR降低的关联强于抗dsDNA。
- 抗dsDNA IgG2在36个月内持续升高且与肾脏结局参数无关。
核心结论
- 抗ENO1、抗H2A和抗ANXA1抗体与LN患者高蛋白尿相关,抗ENO1在12个月内最大程度下降并与蛋白尿减少平行。
- 抗dsDNA抗体与肾脏结局参数无关。
- 新的IgG2抗体特征或可作为LN个体化治疗的示踪物。
研究设计与样本
- 前瞻性分析随访36个月,纳入新诊断LN患者91例、SLE患者31例及诊断2年内SLE患者99例。
- 采用自制方法检测抗足细胞(ENO1)、抗核小体(DNA、H2A、H3)及抗循环蛋白(C1q、ANXA1)IgG2抗体。
- Zeus研究注册于ClinicalTrials.gov,注册号NCT02403115。
主要发现
- 抗ENO1、抗H2A和抗ANXA1 IgG2与蛋白尿平行下降,多数患者在12个月内正常化,而抗dsDNA IgG2在36个月内持续升高。
- 抗ENO1和抗H2A与蛋白尿关联最高(热图),分别识别高蛋白尿患者68%和71%,识别eGFR降低患者均为58%,而抗dsDNA分别为23%和17%(一致性分析)。
- 抗ENO1阳性LN患者基线蛋白尿高于阴性患者,且在12个月内呈现最大降幅。
临床怎么用
- 在LN患者中可检测抗ENO1、抗H2A和抗ANXA1 IgG2抗体以辅助评估蛋白尿相关活动。
- 抗dsDNA IgG2不宜作为肾脏结局参数的关联指标。
- 新IgG2抗体特征有望作为LN个体化治疗的示踪物。
局限性
- 抗体检测采用自制技术,尚未标准化。
- 研究主要聚焦LN患者,其他SLE亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. METHODS: Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n=91) and SLE (n=31) and in other patients with SLE recruited within 2 years from diagnosis (n=99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. RESULTS: LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T0 and presented the maximal decrement within 12 months. CONCLUSIONS: Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. TRIAL REGISTRATION: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).
引用
- Bruschi M, Moroni G, Sinico RA, et al. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study. Rheumatology (Oxford). 2021. PMID: 33351137. doi:10.1093/rheumatology/keaa793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。